Azilsartan mepixetil potassium

Catalog No. :
ACEBPA479
CAS No. :
2153458-32-1
Molecular Formula :
C36H33KN6O8
Molecular Weight :
716.79

IUPAC Name:potassium 3-(4'-((2-ethoxy-7-((1-((((3,5,6-trimethylpyrazin-2-yl)methoxy)carbonyl)oxy)ethoxy)carbonyl)-1H-benzo[d]imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-yl)-5-oxo-1,2,4-oxadiazol-4-ide

Azilsartan mepixetil potassium structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameAzilsartan mepixetil potassium
IUPAC Namepotassium 3-(4'-((2-ethoxy-7-((1-((((3,5,6-trimethylpyrazin-2-yl)methoxy)carbonyl)oxy)ethoxy)carbonyl)-1H-benzo[d]imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-yl)-5-oxo-1,2,4-oxadiazol-4-ide
Molecular FormulaC36H33KN6O8
Molecular Weight716.79
SMILESO=C1[N-]C(C2=CC=CC=C2C3=CC=C(CN4C(OCC)=NC5=CC=CC(C(OC(OC(OCC6=NC(C)=C(C)N=C6C)=O)C)=O)=C45)C=C3)=NO1.[K+]
InChI KeyYGZNXIVTPOLHFN-UHFFFAOYSA-M
SynonymAzilsartan mepixetil potassium;1H-Benzimidazole-7-carboxylic acid, 1-[[2′-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1′-biphenyl]-4-yl]methyl]-2-ethoxy-, 1-[[[(3,5,6-trimethyl-2-pyrazinyl)methoxy]carbonyl]oxy]ethyl ester, potassium salt (1:1)
CAS No.2153458-32-1

Synthetic Route by SureRoute

1. ACEBPA479 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACLBQJ043 route compound structure diagram
    ACLBQJ04375907-74-3 In Stock
  4. Then
  5. ACEBPA479 route product structure diagram
    ACEBPA4792153458-32-1
Inquiry

2. ACEBPA479 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACISJO245 route compound structure diagram
    ACISJO245147403-03-0 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACEBPA479 route product structure diagram
    ACEBPA4792153458-32-1
Inquiry

Comments (0)